Stocktube video
17/03/2014

ReNeuron's retinal treatment potentially in clinical trial in 2014

View full size
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: RENE
Latest Price: 3.70p  (4.82% Ascending)
52-week High: 4.15p
52-week Low: 2.71p
Market Cap: 66.19M
1 year chart More charts
Deal RENE Tax Free*
*subject to change and depends on individual circumstances.
1 day chart More charts
Advertisement
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Deal ReNeuron Tax Free* Losses can exceed
your initial deposit
*subject to change and depends on individual circumstances.

ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

Pdf

ReNeuron raises over £6 million for stem cell research and development

April 27 2012, 7:50am New shares were placed with new investors at 4 pence each

The stem cell specialist ReNeuron (LON:RENE) said it had successfully raised over £6 million to fund its ongoing research and development programme.

Shares were placed with new investors at 4 pence each (last night’s close was 3.99 pence), raising £5.4 million, while existing shareholders were able to participate in the open offer portion of the cash call, adding a further £700,000.

Chief executive Michael Hunt said: “We have raised sufficient overall net proceeds to enable us to progress the company's development strategy to key pre-clinical, regulatory and clinical milestones over the coming year across our core therapeutic programmes."

ReNeuron's ReN001 therapy is currently being used to treat disabled stroke patients as part of the ground-breaking PISCES Study being carried out in Scotland.

In all, 12 stroke sufferers will be given varying doses ReN001 as part of this early-stage trial.

ReNeuron said earlier this month that five patients had been treated in the PISCES stroke study - all three in the first dose cohort and two in the second dose cohort.

No cell-related adverse events or adverse immune-related responses have been reported in any of the patients treated to date, it added, with all five patients seeing some measure of improvement in outcomes, it added.

The company said it expects that the remaining high-dose patient cohorts in the PISCES study will have been treated within the next twelve months, leaving it on-track to submit an application to commence a Phase II study with ReN001 next year.

The ReN001 therapy is based around ReNeuron’s lead neural stem cell line, designated CTX by virtue of its origin from the cortex region of the brain. 

The firm’s other stem cell therapies include ReN009, targeted at peripheral arterial disease , and ReN003, its therapy programme focused on diseases of the retina.

PAD is a chronic, debilitating disease that progressively restricts blood flow in the limbs, causing cramping and chronic pain, and in rare cases it can lead to the loss of a limb. 

During the past year, ReNeuron’s collaborators on its ReN009 programme at the Bristol Heart Institute have presentedpositive pre-clinical efficacy data.

It is continuing to collaborate with the Schepens Eye Research Institute at Havard Medical School on its ReN003 programme.

 

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.